REPL Replimune Group | $7.60
+8.1% | 7/22/2025 | - | Downgrade | Strong-Buy -> Hold | | View details for Leerink Partnrs rating of Replimune Group (NASDAQ:REPL) on 7/22/2025 |
SRPT Sarepta Therapeutics | $15.91
-3.1% | 7/18/2025 | - | Downgrade | Strong-Buy -> Hold | | View details for Leerink Partnrs rating of Sarepta Therapeutics (NASDAQ:SRPT) on 7/18/2025 |
ELV Elevance Health | $274.10
-3.2% | 7/17/2025 | - | Downgrade | Strong-Buy -> Hold | | View details for Leerink Partnrs rating of Elevance Health (NYSE:ELV) on 7/17/2025 |
ZTS Zoetis | $147.40
+1.1% | 7/17/2025 | - | Downgrade | Strong-Buy -> Hold | | View details for Leerink Partnrs rating of Zoetis (NYSE:ZTS) on 7/17/2025 |
ELAN Elanco Animal Health | $13.80
+0.9% | 7/17/2025 | - | Upgrade | Hold -> Strong-Buy | | View details for Leerink Partnrs rating of Elanco Animal Health (NYSE:ELAN) on 7/17/2025 |
RYTM Rhythm Pharmaceuticals | $88.30
+3.6% | 7/7/2025 | F. Khurshid | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of Rhythm Pharmaceuticals (NASDAQ:RYTM) on 7/7/2025 |
PGNY Progyny | $22.49
-4.3% | 7/8/2025 | M. Cherny | Upgrade | Hold -> Strong-Buy | | View details for Leerink Partnrs rating of Progyny (NASDAQ:PGNY) on 7/8/2025 |
ABCL AbCellera Biologics | $4.24
-5.1% | 7/7/2025 | F. Khurshid | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of AbCellera Biologics (NASDAQ:ABCL) on 7/7/2025 |
MDT Medtronic | $89.31
-1.0% | 6/16/2025 | M. Kratky | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of Medtronic (NYSE:MDT) on 6/16/2025 |
BSX Boston Scientific | $105.40
+0.5% | 6/16/2025 | M. Kratky | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of Boston Scientific (NYSE:BSX) on 6/16/2025 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. |
ABT Abbott Laboratories | $127.32
+0.9% | 6/16/2025 | M. Kratky | Upgrade | Hold | | View details for Leerink Partnrs rating of Abbott Laboratories (NYSE:ABT) on 6/16/2025 |
SMMT Summit Therapeutics | $27.07
+2.7% | 6/11/2025 | D. Graybosch | Upgrade | Strong Sell | | View details for Leerink Partnrs rating of Summit Therapeutics (NASDAQ:SMMT) on 6/11/2025 |
ARVN Arvinas | $7.42
-0.3% | 6/1/2025 | A. Berens | Downgrade | Strong-Buy -> Hold | | View details for Leerink Partnrs rating of Arvinas (NASDAQ:ARVN) on 6/1/2025 |
RCKT Rocket Pharmaceuticals | $2.99
-2.0% | 5/27/2025 | M. Foroohar | Downgrade | Strong-Buy -> Hold | | View details for Leerink Partnrs rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 5/27/2025 |
FULC Fulcrum Therapeutics | $6.83
+1.5% | 5/23/2025 | J. Schwartz | Upgrade | Hold -> Strong-Buy | | View details for Leerink Partnrs rating of Fulcrum Therapeutics (NASDAQ:FULC) on 5/23/2025 |
JNJ Johnson & Johnson | $167.33
+1.6% | 5/13/2025 | D. Risinger | Downgrade | Strong-Buy -> Hold | | View details for Leerink Partnrs rating of Johnson & Johnson (NYSE:JNJ) on 5/13/2025 |
ITOS iTeos Therapeutics | $10.09
-0.5% | 5/14/2025 | D. Graybosch | Downgrade | Strong-Buy -> Hold | | View details for Leerink Partnrs rating of iTeos Therapeutics (NASDAQ:ITOS) on 5/14/2025 |
HALO Halozyme Therapeutics | $59.02
-1.6% | 5/13/2025 | D. Risinger | Downgrade | Hold -> Strong Sell | | View details for Leerink Partnrs rating of Halozyme Therapeutics (NASDAQ:HALO) on 5/13/2025 |
AMLX Amylyx Pharmaceuticals | $7.72
-3.9% | 5/6/2025 | M. Goodman | Upgrade | Hold -> Strong-Buy | | View details for Leerink Partnrs rating of Amylyx Pharmaceuticals (NASDAQ:AMLX) on 5/6/2025 |
VRTX Vertex Pharmaceuticals | $462.13
+1.2% | 5/6/2025 | D. Risinger | Downgrade | Strong-Buy -> Hold | | View details for Leerink Partnrs rating of Vertex Pharmaceuticals (NASDAQ:VRTX) on 5/6/2025 |
QTRX Quanterix | $5.86
-1.3% | 4/30/2025 | P. Souda | Downgrade | Strong-Buy -> Hold | | View details for Leerink Partnrs rating of Quanterix (NASDAQ:QTRX) on 4/30/2025 |
NEO NeoGenomics | $5.16
+6.6% | 4/30/2025 | P. Souda | Downgrade | Strong-Buy -> Hold | | View details for Leerink Partnrs rating of NeoGenomics (NASDAQ:NEO) on 4/30/2025 |
AKBA Akebia Therapeutics | $3.72
+1.1% | 4/28/2025 | R. Ruiz | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of Akebia Therapeutics (NASDAQ:AKBA) on 4/28/2025 |
SYRE Spyre Therapeutics | $16.26
-4.2% | 4/8/2025 | F. Khurshid | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of Spyre Therapeutics (NASDAQ:SYRE) on 4/8/2025 |
CMPX Compass Therapeutics | $2.95
-0.7% | 4/1/2025 | A. Berens | Upgrade | Hold -> Strong-Buy | | View details for Leerink Partnrs rating of Compass Therapeutics (NASDAQ:CMPX) on 4/1/2025 |
EQ Equillium | $0.71
+81.6% | 3/28/2025 | T. Smith | Downgrade | Strong-Buy -> Hold | | View details for Leerink Partnrs rating of Equillium (NASDAQ:EQ) on 3/28/2025 |
OPT Opthea | $3.41
+7.2% | 3/24/2025 | M. Goodman | Downgrade | Strong-Buy -> Hold | | View details for Leerink Partnrs rating of Opthea (NASDAQ:OPT) on 3/24/2025 |
MEDP Medpace | $423.09
-1.0% | 3/24/2025 | M. Cherny | Upgrade | Hold | | View details for Leerink Partnrs rating of Medpace (NASDAQ:MEDP) on 3/24/2025 |
ELEV Elevation Oncology | $0.37
| 3/20/2025 | A. Berens | Downgrade | Strong-Buy -> Hold | | View details for Leerink Partnrs rating of Elevation Oncology (NASDAQ:ELEV) on 3/20/2025 |
STTK Shattuck Labs | $0.73
-3.9% | 3/17/2025 | F. Khurshid | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of Shattuck Labs (NASDAQ:STTK) on 3/17/2025 |
NRIX Nurix Therapeutics | $11.04
-2.0% | 3/17/2025 | F. Khurshid | Upgrade | Hold | | View details for Leerink Partnrs rating of Nurix Therapeutics (NASDAQ:NRIX) on 3/17/2025 |
CRMD CorMedix | $11.64
-0.3% | 3/7/2025 | R. Ruiz | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of CorMedix (NASDAQ:CRMD) on 3/7/2025 |
LXRX Lexicon Pharmaceuticals | $1.07
| 3/5/2025 | R. Ruiz | Downgrade | Strong-Buy -> Hold | | View details for Leerink Partnrs rating of Lexicon Pharmaceuticals (NASDAQ:LXRX) on 3/5/2025 |
PLRX Pliant Therapeutics | $1.58
+8.2% | 3/3/2025 | F. Khurshid | Downgrade | Strong-Buy -> Hold | | View details for Leerink Partnrs rating of Pliant Therapeutics (NASDAQ:PLRX) on 3/3/2025 |
MAZE Maze Therapeutics | $14.90
+1.0% | 2/25/2025 | J. Schwartz | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of Maze Therapeutics (NASDAQ:MAZE) on 2/25/2025 |
BBNX Beta Bionics | $16.40
-2.3% | 2/24/2025 | M. Kratky | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of Beta Bionics (NASDAQ:BBNX) on 2/24/2025 |
ATYR aTyr Pharma | $4.70
-0.4% | 2/18/2025 | F. Khurshid | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of aTyr Pharma (NASDAQ:ATYR) on 2/18/2025 |
TXG 10x Genomics | $13.08
-2.8% | 2/13/2025 | P. Souda | Downgrade | Strong-Buy -> Hold | | View details for Leerink Partnrs rating of 10x Genomics (NASDAQ:TXG) on 2/13/2025 |
GMAB Genmab A/S | $21.78
+0.5% | 2/13/2025 | J. Chang | Upgrade | Hold -> Strong-Buy | | View details for Leerink Partnrs rating of Genmab A/S (NASDAQ:GMAB) on 2/13/2025 |
CVS CVS Health | $62.52
+0.7% | 2/12/2025 | M. Cherny | Upgrade | Hold -> Strong-Buy | | View details for Leerink Partnrs rating of CVS Health (NYSE:CVS) on 2/12/2025 |
Microsoft's Next Big Bet? (Ad) Microsoft just broke ground on a revolutionary power system that could deliver virtually limitless, carbon-free energy. Bill Gates calls it “abundant” and is backing four separate startups in the space.
While most of these plays are off-limits to everyday investors, a little-known backdoor could give you access to one tiny company leading the charge—and it’s publicly traded. Get the name and ticker of this breakthrough energy stock before the window closes. |
DOCS Doximity | $57.30
-2.5% | 2/7/2025 | M. Cherny | Upgrade | Hold -> Strong-Buy | | View details for Leerink Partnrs rating of Doximity (NASDAQ:DOCS) on 2/7/2025 |
HOLX Hologic | $67.16
+0.5% | 2/6/2025 | P. Souda | Downgrade | Strong-Buy -> Hold | | View details for Leerink Partnrs rating of Hologic (NASDAQ:HOLX) on 2/6/2025 |
REGN Regeneron Pharmaceuticals | $558.87
+2.5% | 2/5/2025 | D. Risinger | Upgrade | Hold -> Strong-Buy | | View details for Leerink Partnrs rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 2/5/2025 |
DGX Quest Diagnostics | $170.81
+2.0% | 1/6/2025 | M. Cherny | Upgrade | Hold -> Strong-Buy | | View details for Leerink Partnrs rating of Quest Diagnostics (NYSE:DGX) on 1/6/2025 |
ALGN Align Technology | $136.52
+5.8% | 1/6/2025 | M. Cherny | Upgrade | Hold -> Strong-Buy | | View details for Leerink Partnrs rating of Align Technology (NASDAQ:ALGN) on 1/6/2025 |
LVTX LAVA Therapeutics | $1.42
-6.6% | 12/12/2024 | D. Graybosch | Downgrade | Strong-Buy -> Hold | | View details for Leerink Partnrs rating of LAVA Therapeutics (NASDAQ:LVTX) on 12/12/2024 |
QTTB Q32 Bio | $2.00
-9.9% | 12/11/2024 | T. Smith | Downgrade | Strong-Buy -> Hold | | View details for Leerink Partnrs rating of Q32 Bio (NASDAQ:QTTB) on 12/11/2024 |
ANIP ANI Pharmaceuticals | $63.93
+0.9% | 12/11/2024 | F. Khurshid | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of ANI Pharmaceuticals (NASDAQ:ANIP) on 12/11/2024 |
MYGN Myriad Genetics | $3.91
+1.8% | 12/9/2024 | P. Souda | Downgrade | Strong-Buy -> Hold | | View details for Leerink Partnrs rating of Myriad Genetics (NASDAQ:MYGN) on 12/9/2024 |
RLMD Relmada Therapeutics | $0.59
-5.1% | 12/4/2024 | M. Goodman | Downgrade | Strong-Buy -> Hold | | View details for Leerink Partnrs rating of Relmada Therapeutics (NASDAQ:RLMD) on 12/4/2024 |
OKUR OnKure Therapeutics | $2.20
-0.5% | 12/5/2024 | A. Berens | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of OnKure Therapeutics (NASDAQ:OKUR) on 12/5/2024 |
ZTS Zoetis | $147.40
+1.1% | 12/2/2024 | D. Clark | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of Zoetis (NYSE:ZTS) on 12/2/2024 |
IDXX IDEXX Laboratories | $535.54
+0.2% | 12/2/2024 | D. Clark | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of IDEXX Laboratories (NASDAQ:IDXX) on 12/2/2024 |
ELAN Elanco Animal Health | $13.80
+0.9% | 12/2/2024 | D. Clark | Upgrade | Hold | | View details for Leerink Partnrs rating of Elanco Animal Health (NYSE:ELAN) on 12/2/2024 |
CLYM Climb Bio | $1.45
+3.6% | 12/2/2024 | T. Smith | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of Climb Bio (NASDAQ:CLYM) on 12/2/2024 |
JANX Janux Therapeutics | $23.56
-1.9% | 11/22/2024 | J. La. Rosa | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of Janux Therapeutics (NASDAQ:JANX) on 11/22/2024 |
ABBV AbbVie | $195.17
+3.3% | 11/22/2024 | D. Risinger | Upgrade | Hold -> Strong-Buy | | View details for Leerink Partnrs rating of AbbVie (NYSE:ABBV) on 11/22/2024 |
ACRS Aclaris Therapeutics | $1.53
| 11/19/2024 | T. Smith | Upgrade | Hold -> Strong-Buy | | View details for Leerink Partnrs rating of Aclaris Therapeutics (NASDAQ:ACRS) on 11/19/2024 |
CMPX Compass Therapeutics | $2.95
-0.7% | 11/15/2024 | A. Berens | Downgrade | Strong-Buy -> Hold | | View details for Leerink Partnrs rating of Compass Therapeutics (NASDAQ:CMPX) on 11/15/2024 |
MASS 908 Devices | $6.42
-2.0% | 11/13/2024 | P. Souda | Downgrade | Strong-Buy -> Hold | | View details for Leerink Partnrs rating of 908 Devices (NASDAQ:MASS) on 11/13/2024 |
BMY Bristol Myers Squibb | $44.25
+2.2% | 11/12/2024 | D. Risinger | Upgrade | Hold -> Strong-Buy | | View details for Leerink Partnrs rating of Bristol Myers Squibb (NYSE:BMY) on 11/12/2024 |
XRAY DENTSPLY SIRONA | $14.30
-0.1% | 11/7/2024 | M. Cherny | Downgrade | Strong-Buy -> Hold | | View details for Leerink Partnrs rating of DENTSPLY SIRONA (NASDAQ:XRAY) on 11/7/2024 |
ZYME Zymeworks | $12.57
+0.1% | 11/7/2024 | A. Berens | Upgrade | Hold -> Strong-Buy | | View details for Leerink Partnrs rating of Zymeworks (NYSE:ZYME) on 11/7/2024 |
BEAM Beam Therapeutics | $18.83
-4.5% | 11/6/2024 | M. Foroohar | Upgrade | Hold -> Strong-Buy | | View details for Leerink Partnrs rating of Beam Therapeutics (NASDAQ:BEAM) on 11/6/2024 |
IDYA IDEAYA Biosciences | $24.27
-0.3% | 11/5/2024 | A. Berens | Downgrade | Strong-Buy -> Hold | | View details for Leerink Partnrs rating of IDEAYA Biosciences (NASDAQ:IDYA) on 11/5/2024 |
ZURA Zura Bio | $1.50
+7.1% | 11/4/2024 | F. Khurshid | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of Zura Bio (NASDAQ:ZURA) on 11/4/2024 |
NVST Envista | $20.78
+10.0% | 10/31/2024 | M. Cherny | Upgrade | Strong Sell -> Hold | | View details for Leerink Partnrs rating of Envista (NYSE:NVST) on 10/31/2024 |
TENX Tenax Therapeutics | $6.22
-0.3% | 10/24/2024 | D. Risinger | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of Tenax Therapeutics (NASDAQ:TENX) on 10/24/2024 |
GILD Gilead Sciences | $113.18
+0.8% | 10/21/2024 | D. Graybosch | Upgrade | Hold -> Strong-Buy | | View details for Leerink Partnrs rating of Gilead Sciences (NASDAQ:GILD) on 10/21/2024 |
VYGR Voyager Therapeutics | $2.96
-7.2% | 10/16/2024 | L. Nsongo | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of Voyager Therapeutics (NASDAQ:VYGR) on 10/16/2024 |
STOK Stoke Therapeutics | $12.91
+0.5% | 10/11/2024 | M. Goodman | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of Stoke Therapeutics (NASDAQ:STOK) on 10/11/2024 |
MNMD Mind Medicine (MindMed) | $8.44
-7.2% | 10/11/2024 | M. Goodman | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of Mind Medicine (MindMed) (NASDAQ:MNMD) on 10/11/2024 |
MOLN Molecular Partners | $3.53
-4.6% | 10/7/2024 | J. Chang | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of Molecular Partners (NASDAQ:MOLN) on 10/7/2024 |
HUM Humana | $247.19
-1.1% | 10/2/2024 | W. Mayo | Downgrade | Strong-Buy -> Hold | | View details for Leerink Partnrs rating of Humana (NYSE:HUM) on 10/2/2024 |
AGIO Agios Pharmaceuticals | $35.00
-6.0% | 9/27/2024 | A. Berens | Downgrade | Strong-Buy -> Hold | | View details for Leerink Partnrs rating of Agios Pharmaceuticals (NASDAQ:AGIO) on 9/27/2024 |
REGN Regeneron Pharmaceuticals | $558.87
+2.5% | 9/24/2024 | D. Risinger | Downgrade | Strong-Buy -> Hold | | View details for Leerink Partnrs rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 9/24/2024 |
ICLR Icon | $166.44
-1.6% | 9/18/2024 | M. Cherny | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of Icon (NASDAQ:ICLR) on 9/18/2024 |
ORKA Oruka Therapeutics | $13.60
+0.1% | 9/17/2024 | D. Risinger | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of Oruka Therapeutics (NASDAQ:ORKA) on 9/17/2024 |
FULC Fulcrum Therapeutics | $6.83
+1.5% | 9/12/2024 | J. Schwartz | Downgrade | Strong-Buy -> Hold | | View details for Leerink Partnrs rating of Fulcrum Therapeutics (NASDAQ:FULC) on 9/12/2024 |
TRVI Trevi Therapeutics | $7.33
-1.1% | 9/9/2024 | F. Khurshid | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of Trevi Therapeutics (NASDAQ:TRVI) on 9/9/2024 |
PRTC PureTech Health | $19.09
+2.1% | 9/9/2024 | F. Khurshid | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of PureTech Health (NASDAQ:PRTC) on 9/9/2024 |
PLRX Pliant Therapeutics | $1.58
+8.2% | 9/9/2024 | F. Khurshid | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of Pliant Therapeutics (NASDAQ:PLRX) on 9/9/2024 |
MNKD MannKind | $3.75
-0.8% | 9/9/2024 | F. Khurshid | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of MannKind (NASDAQ:MNKD) on 9/9/2024 |
KYMR Kymera Therapeutics | $42.96
-1.8% | 9/9/2024 | F. Khurshid | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of Kymera Therapeutics (NASDAQ:KYMR) on 9/9/2024 |
IRWD Ironwood Pharmaceuticals | $0.77
+1.0% | 9/9/2024 | F. Khurshid | Upgrade | Hold | | View details for Leerink Partnrs rating of Ironwood Pharmaceuticals (NASDAQ:IRWD) on 9/9/2024 |
IMUX Immunic | $0.93
-0.9% | 9/9/2024 | F. Khurshid | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of Immunic (NASDAQ:IMUX) on 9/9/2024 |
GERN Geron | $1.17
+1.7% | 9/9/2024 | F. Khurshid | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of Geron (NASDAQ:GERN) on 9/9/2024 |
TXG 10x Genomics | $13.08
-2.8% | 9/3/2024 | P. Souda | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of 10x Genomics (NASDAQ:TXG) on 9/3/2024 |
PEN Penumbra | $242.50
-3.9% | 9/3/2024 | M. Kratky | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of Penumbra (NYSE:PEN) on 9/3/2024 |
ARDT Ardent Health | $10.21
-3.7% | 8/12/2024 | W. Mayo | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of Ardent Health (NYSE:ARDT) on 8/12/2024 |
Microsoft's Next Big Bet? (Ad) Microsoft just broke ground on a revolutionary power system that could deliver virtually limitless, carbon-free energy. Bill Gates calls it “abundant” and is backing four separate startups in the space.
While most of these plays are off-limits to everyday investors, a little-known backdoor could give you access to one tiny company leading the charge—and it’s publicly traded. Get the name and ticker of this breakthrough energy stock before the window closes. |
ARCT Arcturus Therapeutics | $12.30
+0.7% | 8/12/2024 | L. Nsongo | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of Arcturus Therapeutics (NASDAQ:ARCT) on 8/12/2024 |
PGNY Progyny | $22.49
-4.3% | 8/7/2024 | M. Cherny | Downgrade | Strong-Buy -> Hold | | View details for Leerink Partnrs rating of Progyny (NASDAQ:PGNY) on 8/7/2024 |
TBPH Theravance Biopharma | $10.90
-2.3% | 8/6/2024 | D. Risinger | Downgrade | Strong-Buy -> Hold | | View details for Leerink Partnrs rating of Theravance Biopharma (NASDAQ:TBPH) on 8/6/2024 |
WAT Waters | $290.77
+0.7% | 8/1/2024 | P. Souda | Upgrade | Hold -> Strong-Buy | | View details for Leerink Partnrs rating of Waters (NYSE:WAT) on 8/1/2024 |
TECX Tectonic Therapeutic | $20.73
-6.6% | 7/24/2024 | D. Risinger | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of Tectonic Therapeutic (NASDAQ:TECX) on 7/24/2024 |
IONS Ionis Pharmaceuticals | $43.03
+0.1% | 7/24/2024 | M. Foroohar | Upgrade | Hold -> Strong-Buy | | View details for Leerink Partnrs rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 7/24/2024 |
ALMS Alumis | $4.13
-0.2% | 7/23/2024 | T. Smith | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of Alumis (NASDAQ:ALMS) on 7/23/2024 |
CELC Celcuity | $39.91
+1.9% | 7/22/2024 | A. Berens | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of Celcuity (NASDAQ:CELC) on 7/22/2024 |
BNTC Benitec Biopharma | $10.96
+0.3% | 7/22/2024 | M. Foroohar | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of Benitec Biopharma (NASDAQ:BNTC) on 7/22/2024 |
EHC Encompass Health | $108.67
-1.3% | 7/10/2024 | W. Mayo | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of Encompass Health (NYSE:EHC) on 7/10/2024 |
HLVX HilleVax | $2.04
-3.3% | 7/9/2024 | D. Risinger | Downgrade | Strong-Buy -> Hold | | View details for Leerink Partnrs rating of HilleVax (NASDAQ:HLVX) on 7/9/2024 |
RVTY Revvity | $88.20
+0.3% | 7/8/2024 | P. Souda | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of Revvity (NYSE:RVTY) on 7/8/2024 |
SDGR Schrodinger | $19.53
-3.9% | 7/2/2024 | M. Foroohar | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of Schrodinger (NASDAQ:SDGR) on 7/2/2024 |
SLDB Solid Biosciences | $6.83
-0.1% | 6/24/2024 | J. Schwartz | Upgrade | Hold -> Strong-Buy | | View details for Leerink Partnrs rating of Solid Biosciences (NASDAQ:SLDB) on 6/24/2024 |
QTTB Q32 Bio | $2.00
-9.9% | 5/21/2024 | T. Smith | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of Q32 Bio (NASDAQ:QTTB) on 5/21/2024 |
BOLT Bolt Biotherapeutics | $5.53
-2.1% | 5/14/2024 | D. Graybosch | Downgrade | Strong-Buy -> Hold | | View details for Leerink Partnrs rating of Bolt Biotherapeutics (NASDAQ:BOLT) on 5/14/2024 |
EHAB Enhabit | $6.53
-2.8% | 5/14/2024 | W. Mayo | Upgrade | Strong Sell -> Hold | | View details for Leerink Partnrs rating of Enhabit (NYSE:EHAB) on 5/14/2024 |
AIRS AirSculpt Technologies | $5.91
-10.6% | 5/14/2024 | W. Mayo | Downgrade | Strong-Buy -> Hold | | View details for Leerink Partnrs rating of AirSculpt Technologies (NASDAQ:AIRS) on 5/14/2024 |
AQST Aquestive Therapeutics | $3.82
-0.5% | 5/10/2024 | R. Ruiz | Upgrade | Strong-Buy | | View details for Leerink Partnrs rating of Aquestive Therapeutics (NASDAQ:AQST) on 5/10/2024 |
MYGN Myriad Genetics | $3.91
+1.8% | 5/8/2024 | P. Souda | Upgrade | Market Perform -> Outperform | | View details for Leerink Partnrs rating of Myriad Genetics (NASDAQ:MYGN) on 5/8/2024 |
BPMC Blueprint Medicines | $129.46
| 5/6/2024 | A. Berens | Upgrade | Underperform -> Market Perform | | View details for Leerink Partnrs rating of Blueprint Medicines (NASDAQ:BPMC) on 5/6/2024 |
CVS CVS Health | $62.52
+0.7% | 5/1/2024 | M. Cherny | Downgrade | Outperform -> Market Perform | | View details for Leerink Partnrs rating of CVS Health (NYSE:CVS) on 5/1/2024 |
XOMA XOMA Royalty | $24.77
-0.4% | 4/29/2024 | D. Risinger | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of XOMA Royalty (NASDAQ:XOMA) on 4/29/2024 |
LXRX Lexicon Pharmaceuticals | $1.07
| 4/30/2024 | R. Ruiz | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of Lexicon Pharmaceuticals (NASDAQ:LXRX) on 4/30/2024 |
IMCR Immunocore | $32.99
+0.7% | 4/29/2024 | J. Chang | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of Immunocore (NASDAQ:IMCR) on 4/29/2024 |
NGNE Neurogene | $21.78
+0.0% | 4/29/2024 | M. Foroohar | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of Neurogene (NASDAQ:NGNE) on 4/29/2024 |
TNDM Tandem Diabetes Care | $15.40
-1.2% | 4/25/2024 | M. Kratky | Upgrade | Market Perform -> Outperform | | View details for Leerink Partnrs rating of Tandem Diabetes Care (NASDAQ:TNDM) on 4/25/2024 |
CVAC CureVac | $5.41
+0.4% | 4/25/2024 | M. Foroohar | Downgrade | Outperform -> Market Perform | | View details for Leerink Partnrs rating of CureVac (NASDAQ:CVAC) on 4/25/2024 |
RNAC Cartesian Therapeutics | $12.33
-3.7% | 4/23/2024 | T. Smith | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of Cartesian Therapeutics (NASDAQ:RNAC) on 4/23/2024 |
ANAB AnaptysBio | $24.69
+0.6% | 4/16/2024 | D. Risinger | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of AnaptysBio (NASDAQ:ANAB) on 4/16/2024 |
MNMD Mind Medicine (MindMed) | $8.44
-7.2% | 4/15/2024 | R. Li | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of Mind Medicine (MindMed) (NASDAQ:MNMD) on 4/15/2024 |
LENZ LENZ Therapeutics | $29.96
+0.6% | 4/15/2024 | M. Goodman | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of LENZ Therapeutics (NASDAQ:LENZ) on 4/15/2024 |
ARDX Ardelyx | $4.33
+2.1% | 4/5/2024 | R. Ruiz | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of Ardelyx (NASDAQ:ARDX) on 4/5/2024 |
LRMR Larimar Therapeutics | $3.44
-0.6% | 4/3/2024 | J. Park | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of Larimar Therapeutics (NASDAQ:LRMR) on 4/3/2024 |
NUVL Nuvalent | $77.76
-0.8% | 4/1/2024 | A. Berens | Upgrade | Market Perform -> Outperform | | View details for Leerink Partnrs rating of Nuvalent (NASDAQ:NUVL) on 4/1/2024 |
SGMT Sagimet Biosciences | $8.25
-5.1% | 3/25/2024 | T. Smith | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of Sagimet Biosciences (NASDAQ:SGMT) on 3/25/2024 |
AMLX Amylyx Pharmaceuticals | $7.72
-3.9% | 3/11/2024 | M. Goodman | Downgrade | Outperform -> Market Perform | | View details for Leerink Partnrs rating of Amylyx Pharmaceuticals (NASDAQ:AMLX) on 3/11/2024 |
RGNX REGENXBIO | $8.19
-3.8% | 3/6/2024 | M. Foroohar | Upgrade | Market Perform -> Outperform | | View details for Leerink Partnrs rating of REGENXBIO (NASDAQ:RGNX) on 3/6/2024 |
SPRY ARS Pharmaceuticals | $17.18
-2.8% | 3/5/2024 | R. Ruiz | Upgrade | Market Perform -> Outperform | | View details for Leerink Partnrs rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 3/5/2024 |
KYTX Kyverna Therapeutics | $3.44
-3.6% | 3/4/2024 | T. Smith | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of Kyverna Therapeutics (NASDAQ:KYTX) on 3/4/2024 |
IDYA IDEAYA Biosciences | $24.27
-0.3% | 2/23/2024 | A. Berens | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of IDEAYA Biosciences (NASDAQ:IDYA) on 2/23/2024 |
DOCS Doximity | $57.30
-2.5% | 2/26/2024 | M. Cherny | Reiterated Rating | Market Perform | | View details for Leerink Partnrs rating of Doximity (NASDAQ:DOCS) on 2/26/2024 |
CERT Certara | $9.54
-3.0% | 2/26/2024 | M. Cherny | Reiterated Rating | Market Perform | | View details for Leerink Partnrs rating of Certara (NASDAQ:CERT) on 2/26/2024 |
XRAY DENTSPLY SIRONA | $14.30
-0.1% | 2/26/2024 | M. Cherny | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of DENTSPLY SIRONA (NASDAQ:XRAY) on 2/26/2024 |
RLAY Relay Therapeutics | $3.36
-4.5% | 2/22/2024 | A. Berens | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of Relay Therapeutics (NASDAQ:RLAY) on 2/22/2024 |
PGNY Progyny | $22.49
-4.3% | 2/26/2024 | M. Cherny | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of Progyny (NASDAQ:PGNY) on 2/26/2024 |
NVST Envista | $20.78
+10.0% | 2/26/2024 | M. Cherny | Reiterated Rating | Underperform | | View details for Leerink Partnrs rating of Envista (NYSE:NVST) on 2/26/2024 |
NUVL Nuvalent | $77.76
-0.8% | 2/22/2024 | A. Berens | Reiterated Rating | Market Perform | | View details for Leerink Partnrs rating of Nuvalent (NASDAQ:NUVL) on 2/22/2024 |
LH Labcorp | $261.34
+0.5% | 2/26/2024 | M. Cherny | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of Labcorp (NYSE:LH) on 2/26/2024 |
DGX Quest Diagnostics | $170.81
+2.0% | 2/26/2024 | M. Cherny | Reiterated Rating | Market Perform | | View details for Leerink Partnrs rating of Quest Diagnostics (NYSE:DGX) on 2/26/2024 |
One stock to replace Nvidia (Ad) Investing Legend Hints the End May be Near for These 3 Iconic Stocks
One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast. Click to get the full details on Eric Fry's "Nvidia alternative" right here. |
COGT Cogent Biosciences | $11.40
-0.2% | 2/22/2024 | A. Berens | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of Cogent Biosciences (NASDAQ:COGT) on 2/22/2024 |
ARVN Arvinas | $7.42
-0.3% | 2/22/2024 | A. Berens | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of Arvinas (NASDAQ:ARVN) on 2/22/2024 |
ALGN Align Technology | $136.52
+5.8% | 2/26/2024 | M. Cherny | Reiterated Rating | Market Perform | | View details for Leerink Partnrs rating of Align Technology (NASDAQ:ALGN) on 2/26/2024 |
WBA Walgreens Boots Alliance | $11.64
| 2/26/2024 | M. Cherny | Reiterated Rating | Market Perform | | View details for Leerink Partnrs rating of Walgreens Boots Alliance (NASDAQ:WBA) on 2/26/2024 |
TDOC Teladoc Health | $6.94
-3.7% | 2/26/2024 | M. Cherny | Reiterated Rating | Market Perform | | View details for Leerink Partnrs rating of Teladoc Health (NYSE:TDOC) on 2/26/2024 |
PINC Premier | $21.27
-1.0% | 2/26/2024 | S. Davis | Reiterated Rating | Market Perform | | View details for Leerink Partnrs rating of Premier (NASDAQ:PINC) on 2/26/2024 |
OMI Owens & Minor | $6.61
-4.6% | 2/26/2024 | M. Cherny | Reiterated Rating | Market Perform | | View details for Leerink Partnrs rating of Owens & Minor (NYSE:OMI) on 2/26/2024 |
MCK McKesson | $698.43
+0.7% | 2/26/2024 | M. Cherny | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of McKesson (NYSE:MCK) on 2/26/2024 |
IQV IQVIA | $182.44
-1.8% | 2/26/2024 | S. Davis | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of IQVIA (NYSE:IQV) on 2/26/2024 |
HSIC Henry Schein | $67.98
+0.5% | 2/26/2024 | M. Cherny | Reiterated Rating | Market Perform | | View details for Leerink Partnrs rating of Henry Schein (NASDAQ:HSIC) on 2/26/2024 |
HIMS Hims & Hers Health | $62.57
-5.5% | 2/26/2024 | M. Cherny | Reiterated Rating | Market Perform | | View details for Leerink Partnrs rating of Hims & Hers Health (NYSE:HIMS) on 2/26/2024 |
GDRX GoodRx | $4.53
-5.4% | 2/26/2024 | S. Davis | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of GoodRx (NASDAQ:GDRX) on 2/26/2024 |
CVS CVS Health | $62.52
+0.7% | 2/26/2024 | M. Cherny | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of CVS Health (NYSE:CVS) on 2/26/2024 |
COR Cencora | $288.31
+0.8% | 2/26/2024 | M. Cherny | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of Cencora (NYSE:COR) on 2/26/2024 |
CAH Cardinal Health | $155.97
+0.5% | 2/26/2024 | M. Cherny | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of Cardinal Health (NYSE:CAH) on 2/26/2024 |
APLT Applied Therapeutics | $0.44
-2.1% | 2/22/2024 | J. Schwartz | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of Applied Therapeutics (NASDAQ:APLT) on 2/22/2024 |
RAPT Rapt Therapeutics | $10.49
-2.9% | 2/21/2024 | T. Smith | Downgrade | Outperform -> Market Perform | | View details for Leerink Partnrs rating of Rapt Therapeutics (NASDAQ:RAPT) on 2/21/2024 |
ENGN enGene | $3.83
+1.1% | 2/20/2024 | M. Foroohar | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of enGene (NASDAQ:ENGN) on 2/20/2024 |
BTSG BrightSpring Health Services | $19.64
-4.9% | 2/20/2024 | W. Mayo | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of BrightSpring Health Services (NASDAQ:BTSG) on 2/20/2024 |
SYBX Synlogic | $1.48
-3.9% | 2/9/2024 | J. Schwartz | Downgrade | Outperform -> Market Perform | | View details for Leerink Partnrs rating of Synlogic (NASDAQ:SYBX) on 2/9/2024 |
AMGN Amgen | $296.88
+0.6% | 2/7/2024 | D. Risinger | Downgrade | Outperform -> Market Perform | | View details for Leerink Partnrs rating of Amgen (NASDAQ:AMGN) on 2/7/2024 |
UTHR United Therapeutics | $294.28
+7.1% | 2/5/2024 | R. Ruiz | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of United Therapeutics (NASDAQ:UTHR) on 2/5/2024 |
NPCE NeuroPace | $8.99
+5.6% | 1/30/2024 | M. Kratky | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of NeuroPace (NASDAQ:NPCE) on 1/30/2024 |
IMNM Immunome | $10.59
+0.7% | 1/29/2024 | A. Berens | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of Immunome (NASDAQ:IMNM) on 1/29/2024 |
PYXS Pyxis Oncology | $1.10
-1.8% | 1/23/2024 | J. La. Rosa | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of Pyxis Oncology (NASDAQ:PYXS) on 1/23/2024 |
AGL Agilon Health | $1.70
-5.3% | 1/8/2024 | W. Mayo | Downgrade | Outperform -> Market Perform | | View details for Leerink Partnrs rating of Agilon Health (NYSE:AGL) on 1/8/2024 |
ALVR AlloVir | $2.68
-0.4% | 12/22/2023 | M. Foroohar | Downgrade | Outperform -> Market Perform | | View details for Leerink Partnrs rating of AlloVir (NASDAQ:ALVR) on 12/22/2023 |
WVE WAVE Life Sciences | $8.63
+6.5% | 12/19/2023 | J. Schwartz | Upgrade | Market Perform -> Outperform | | View details for Leerink Partnrs rating of WAVE Life Sciences (NASDAQ:WVE) on 12/19/2023 |
NBTX Nanobiotix | $6.74
-2.4% | 12/8/2023 | J. Chang | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of Nanobiotix (NASDAQ:NBTX) on 12/8/2023 |
TRML Tourmaline Bio | $21.76
-1.7% | 12/7/2023 | T. Smith | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of Tourmaline Bio (NASDAQ:TRML) on 12/7/2023 |
MOR MorphoSys | $18.96
| 12/6/2023 | A. Berens | Reiterated Rating | Market Perform | | View details for Leerink Partnrs rating of MorphoSys (NASDAQ:MOR) on 12/6/2023 |
TNYA Tenaya Therapeutics | $0.67
-0.8% | 11/30/2023 | M. Foroohar | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of Tenaya Therapeutics (NASDAQ:TNYA) on 11/30/2023 |
LXEO Lexeo Therapeutics | $4.61
-2.5% | 11/28/2023 | M. Foroohar | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of Lexeo Therapeutics (NASDAQ:LXEO) on 11/28/2023 |
ABVX Abivax | $71.94
+0.2% | 11/14/2023 | T. Smith | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of Abivax (NASDAQ:ABVX) on 11/14/2023 |
ACRS Aclaris Therapeutics | $1.53
| 11/13/2023 | T. Smith | Downgrade | Outperform -> Market Perform | | View details for Leerink Partnrs rating of Aclaris Therapeutics (NASDAQ:ACRS) on 11/13/2023 |
ZNTL Zentalis Pharmaceuticals | $1.34
-2.9% | 11/7/2023 | A. Berens | Downgrade | Outperform -> Market Perform | | View details for Leerink Partnrs rating of Zentalis Pharmaceuticals (NASDAQ:ZNTL) on 11/7/2023 |
BEAM Beam Therapeutics | $18.83
-4.5% | 10/20/2023 | M. Foroohar | Downgrade | Outperform -> Market Perform | | View details for Leerink Partnrs rating of Beam Therapeutics (NASDAQ:BEAM) on 10/20/2023 |
FDMT 4D Molecular Therapeutics | $6.42
+42.7% | 10/18/2023 | M. Foroohar | Upgrade | Market Perform -> Outperform | | View details for Leerink Partnrs rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 10/18/2023 |
PLRX Pliant Therapeutics | $1.58
+8.2% | 10/16/2023 | T. Smith | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of Pliant Therapeutics (NASDAQ:PLRX) on 10/16/2023 |
KYMR Kymera Therapeutics | $42.96
-1.8% | 10/16/2023 | T. Smith | Reiterated Rating | Market Perform | | View details for Leerink Partnrs rating of Kymera Therapeutics (NASDAQ:KYMR) on 10/16/2023 |
VCEL Vericel | $35.63
+2.0% | 10/16/2023 | M. Kratky | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of Vericel (NASDAQ:VCEL) on 10/16/2023 |
TNDM Tandem Diabetes Care | $15.40
-1.2% | 10/16/2023 | M. Kratky | Reiterated Rating | Market Perform | | View details for Leerink Partnrs rating of Tandem Diabetes Care (NASDAQ:TNDM) on 10/16/2023 |
PRCT PROCEPT BioRobotics | $49.96
+3.0% | 10/16/2023 | M. Kratky | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of PROCEPT BioRobotics (NASDAQ:PRCT) on 10/16/2023 |
PODD Insulet | $284.91
-1.2% | 10/16/2023 | M. Kratky | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of Insulet (NASDAQ:PODD) on 10/16/2023 |
INSP Inspire Medical Systems | $126.15
+1.3% | 10/16/2023 | M. Kratky | Reiterated Rating | Market Perform | | View details for Leerink Partnrs rating of Inspire Medical Systems (NYSE:INSP) on 10/16/2023 |
EW Edwards Lifesciences | $79.30
0.0% | 10/16/2023 | M. Kratky | Reiterated Rating | Market Perform | | View details for Leerink Partnrs rating of Edwards Lifesciences (NYSE:EW) on 10/16/2023 |
DXCM DexCom | $79.28
-1.8% | 10/16/2023 | M. Kratky | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of DexCom (NASDAQ:DXCM) on 10/16/2023 |
GILD Gilead Sciences | $113.18
+0.8% | 10/11/2023 | D. Graybosch | Reiterated Rating | Market Perform | | View details for Leerink Partnrs rating of Gilead Sciences (NASDAQ:GILD) on 10/11/2023 |
AMGN Amgen | $296.88
+0.6% | 10/11/2023 | D. Risinger | Upgrade | Market Perform -> Outperform | | View details for Leerink Partnrs rating of Amgen (NASDAQ:AMGN) on 10/11/2023 |
ACLX Arcellx | $71.14
-0.4% | 10/12/2023 | D. Graybosch | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of Arcellx (NASDAQ:ACLX) on 10/12/2023 |
One stock to replace Nvidia (Ad) Investing Legend Hints the End May be Near for These 3 Iconic Stocks
One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast. Click to get the full details on Eric Fry's "Nvidia alternative" right here. |
SPRY ARS Pharmaceuticals | $17.18
-2.8% | 9/21/2023 | R. Ruiz | Downgrade | Outperform -> Market Perform | | View details for Leerink Partnrs rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 9/21/2023 |
DSGN Design Therapeutics | $3.82
-1.3% | 8/15/2023 | J. Schwartz | Downgrade | Outperform -> Market Perform | | View details for Leerink Partnrs rating of Design Therapeutics (NASDAQ:DSGN) on 8/15/2023 |
CYTK Cytokinetics | $36.69
-2.5% | 8/15/2023 | R. Ruiz | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of Cytokinetics (NASDAQ:CYTK) on 8/15/2023 |
RLAY Relay Therapeutics | $3.36
-4.5% | 8/8/2023 | C. Liu | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of Relay Therapeutics (NASDAQ:RLAY) on 8/8/2023 |
NUVL Nuvalent | $77.76
-0.8% | 8/8/2023 | C. Liu | Reiterated Rating | Market Perform | | View details for Leerink Partnrs rating of Nuvalent (NASDAQ:NUVL) on 8/8/2023 |
IDYA IDEAYA Biosciences | $24.27
-0.3% | 8/8/2023 | C. Liu | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of IDEAYA Biosciences (NASDAQ:IDYA) on 8/8/2023 |
EXEL Exelixis | $37.26
+2.9% | 8/8/2023 | C. Liu | Reiterated Rating | Market Perform | | View details for Leerink Partnrs rating of Exelixis (NASDAQ:EXEL) on 8/8/2023 |
QTRX Quanterix | $5.86
-1.3% | 8/8/2023 | P. Souda | Upgrade | Market Perform -> Outperform | | View details for Leerink Partnrs rating of Quanterix (NASDAQ:QTRX) on 8/8/2023 |
NVCR NovoCure | $11.32
-2.2% | 8/4/2023 | J. Chang | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of NovoCure (NASDAQ:NVCR) on 8/4/2023 |
WVE WAVE Life Sciences | $8.63
+6.5% | 8/4/2023 | J. Schwartz | Reiterated Rating | Market Perform | | View details for Leerink Partnrs rating of WAVE Life Sciences (NASDAQ:WVE) on 8/4/2023 |
BLTE Belite Bio | $65.72
+1.1% | 7/26/2023 | M. Goodman | Reiterated Rating | Outperform | | View details for Leerink Partnrs rating of Belite Bio (NASDAQ:BLTE) on 7/26/2023 |
